How Medicine Forgot Women: A Missed Opportunity for Asia

How Medicine Forgot Women: A Missed Opportunity for Asia

For decades, medical research has disproportionately focused on male physiology, leading to a significant gap in understanding and treating diseases in women. As Asia's healthcare landscape evolves, it has a critical opportunity to lead in addressing this historical oversight. For pharmaceutical companies and investors evaluating growth markets, the systemic neglect of female health represents both a moral liability and a multi-billion-dollar unmet need that will reshape competitive positioning across the region.

Key Takeaways

• Historical exclusion of women from clinical trials created a knowledge gap that persists in pharmacovigilance, dosing, and therapeutic efficacy today.
• Conditions prevalent among women in South Asia—including anemia, maternal mortality, and reproductive health disorders—remain chronically under-researched relative to their disease burden.
• Asia's expanding healthcare infrastructure and large female demographic offer pharmaceutical companies first-mover advantages through gender-inclusive trial design and targeted market entry.
• Companies that embed sex-disaggregated data and female-specific endpoints into their Asia strategies will capture share as payers and regulators demand equitable evidence.
• Regulators in Japan, South Korea, and increasingly India are signaling expectations for sex-balanced enrollment, making inclusive trial design a compliance imperative as well as a commercial one.

Why Were Women Excluded from Medical Research?

Modern pharmacology was built on a foundation that treated the male body as the default human model. Through much of the 20th century, clinical trials enrolled predominantly male subjects, driven by a combination of paternalistic concerns about reproductive risk and a genuine belief that male physiology was a sufficient proxy for all patients. The result was a "one-size-fits-all" framework that assumed drug metabolism, disease presentation, and treatment response were essentially identical across sexes.

This assumption proved costly. Aspirin's cardioprotective effects, for instance, were established largely through trials enrolling men; subsequent research revealed that the drug's benefit profile differs meaningfully in women. Similarly, sleep medications and certain cardiovascular drugs were approved at doses calibrated for male body weight and metabolism, leading to higher rates of adverse events in women. The FDA eventually identified that women experienced adverse drug reactions at roughly twice the rate of men—a disparity rooted not in biology alone, but in the absence of sex-specific data at the point of approval.

Reproductive health conditions, autoimmune disorders, and diseases like endometriosis have languished in underfunded research pipelines for years. Endometriosis, which affects an estimated 10% of reproductive-age women globally, took an average of seven to ten years to diagnose in Western health systems—a delay that reflects the broader pattern of dismissing or minimizing women's pain. As NIH research on gender and health disparity in South Asia documents, these global patterns of neglect intersect with regional structural barriers to create compounding disadvantages for women.

What Are the Consequences of the Gender Health Gap?

The downstream effects of this neglect are measurable and severe. Women are more likely to be misdiagnosed for conditions that present atypically relative to male norms, particularly in cardiology, neurology, and pain management. They are more likely to receive psychosomatic explanations for physical symptoms, a pattern documented across multiple health systems and referred to as the "gender pain gap." UN Women has catalogued how women remain less likely to be taken seriously, diagnosed, or treated—a systemic bias that transcends individual clinician behavior.

In South Asia, these global patterns intersect with regional disparities in access, education, and social determinants of health. Anemia illustrates the scale of the problem: over 50% of Indian women aged 15–49 are anemic, a prevalence that has persisted despite decades of public health programming. The condition contributes to maternal mortality, reduced workforce productivity, and generational health consequences for children born to anemic mothers. Yet research into context-specific interventions—accounting for dietary patterns, genetic factors, and co-infections prevalent in South Asia—remains fragmented.

As the NIH analysis of South Asian gender health disparity notes, women in the region face structural barriers that compound the biological knowledge gap. Cultural norms around women's autonomy, limited health literacy, and uneven access to primary care mean that even when effective treatments exist, they often fail to reach the patients who need them most. The result is a cycle in which under-research leads to under-treatment, which in turn reinforces the perception that women's health conditions are intractable rather than addressable.

Why Can't Asia Afford to Repeat This Mistake?

Asia is home to more than 2.3 billion women, a demographic that is aging, urbanizing, and increasingly engaged with formal healthcare systems. The region's pharmaceutical market is projected to grow significantly through 2030, driven by expanding insurance coverage, government health initiatives, and rising chronic disease burden. This growth trajectory creates a structural imperative: build gender-inclusive evidence now, or inherit the same diagnostic and therapeutic blind spots that have plagued Western medicine.

The economic argument is straightforward. Women's health conditions impose substantial costs on families, employers, and health systems through lost productivity, repeated hospitalizations, and long-term disability. Investing in female-specific research and care delivery generates returns that compound over time—healthier women participate more fully in the economy, raise healthier children, and reduce the downstream burden on acute care systems.

Asia also has the advantage of learning from Western missteps. Regulatory frameworks, clinical trial infrastructure, and digital health platforms are being built in real time across markets like India, China, South Korea, and Southeast Asia. Embedding sex-disaggregated data collection, female-specific endpoints, and gender-balanced enrollment into these systems from inception is far less costly than retrofitting them later.

Where Are the Strategic Opportunities for Pharma in Asia?

For BD teams and strategists evaluating the Asia women's health market, several high-value opportunities are emerging. First, the sheer prevalence of conditions like anemia, polycystic ovary syndrome, gestational diabetes, and cervical cancer in Asian populations creates immediate demand for therapeutics, diagnostics, and preventive products tailored to regional epidemiology.

Second, inclusive clinical trial design is becoming a competitive differentiator. Regulators in Japan, South Korea, and increasingly India are signaling expectations for sex-balanced enrollment and subgroup analysis. Companies that proactively design trials with these requirements—rather than scrambling to generate post-hoc data—will secure faster approvals and stronger formulary positioning.

Third, partnerships with regional health organizations, government ministries, and academic institutions offer pathways to both market access and evidence generation. Collaborative research programs that address locally prevalent women's health conditions build goodwill, generate real-world data, and create barriers to entry for competitors who lack on-the-ground relationships.

The competitive landscape is still taking shape. Global specialty pharma companies with established women's health portfolios are evaluating Asia expansion, while regional players are building domestic capabilities in reproductive health, maternal-fetal medicine, and chronic disease management. First movers that combine scientific rigor with cultural competence—understanding how gender norms, family structures, and health-seeking behaviors vary across Asian markets—will define the category.

How Can Companies Build Gender-Inclusive Clinical Trials in Asia?

The practical challenge for pharmaceutical companies is translating intent into trial design. Sex-balanced enrollment sounds straightforward, but achieving it requires addressing recruitment barriers that are specific to each market. In parts of South Asia, women's participation in clinical research is constrained by household decision-making dynamics, mobility restrictions, and distrust of institutional medicine. Companies that invest in community-based recruitment, female investigator teams, and culturally adapted consent processes will enroll women more effectively—and generate data that regulators and payers will trust.

Endpoints matter too. Cardiovascular outcomes trials that use male-pattern symptom presentation as the primary endpoint will miss sex-differentiated efficacy signals. The FDA's guidance on enhancing the diversity of clinical trial populations explicitly calls for sex-disaggregated analysis, and companies operating in Asia should anticipate similar expectations from regional regulators. Building these analyses into Phase III protocols now avoids costly post-marketing commitments later.

Data infrastructure is the third pillar. Electronic health records, claims databases, and patient registries across Asia are still maturing, and few currently capture sex-disaggregated outcomes at the granularity needed for pharmacovigilance. Companies that partner with hospital networks and digital health platforms to build these datasets will create proprietary evidence assets that competitors cannot easily replicate.

Frequently Asked Questions

Related coverage

• Asia Pacific eClinical Solutions Market Report 2025-2030: Key Insights
• Biomarkers and Digital Technologies Transforming Oncology in Asia
• PREMIA and Lind Expand AI-Powered Clinical Trial Screening Across Asia-Pacific